125 related articles for article (PubMed ID: 20587321)
1. [The association between NAT2 polymorphism and anti-tuberculosis drug-induced hepatitis].
Wu YM; Luo ZY; Zhang HM; Peng JF; Liu SY; Wang M
Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):467-9. PubMed ID: 20587321
[No Abstract] [Full Text] [Related]
2. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
Shi J; Xie M; Wang J; Xu Y; Liu X
Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
[TBL] [Abstract][Full Text] [Related]
5. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
6. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
8. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
[TBL] [Abstract][Full Text] [Related]
9. Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation.
Cramer JP; Lohse AW; Burchard GD; Fischer L; Nashan B; Zimmermann M; Marx A; Kluge S
Transpl Int; 2010 Feb; 23(2):231-3. PubMed ID: 19686464
[No Abstract] [Full Text] [Related]
10. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
Araujo-Mariz C; Militão de Albuquerque MFP; Lopes EP; Ximenes RAA; Lacerda HR; Miranda-Filho DB; Lustosa-Martins BB; Pastor AFP; Acioli-Santos B
Ann Hepatol; 2020; 19(2):153-160. PubMed ID: 31734174
[TBL] [Abstract][Full Text] [Related]
11. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
Yamada S; Tang M; Richardson K; Halaschek-Wiener J; Chan M; Cook VJ; Fitzgerald JM; Elwood RK; Brooks-Wilson A; Marra F
Pharmacogenomics; 2009 Sep; 10(9):1433-45. PubMed ID: 19761367
[TBL] [Abstract][Full Text] [Related]
12. [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
Negri L; Le Grusse J; Séraissol P; Lavit M; Houin G; Gandia P
Therapie; 2014; 69(6):509-16. PubMed ID: 25314930
[TBL] [Abstract][Full Text] [Related]
13. A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India.
Shetty P; Panchal F; Munshi R; Sundar U; Darole P
Indian J Tuberc; 2020 Jul; 67(3):407-410. PubMed ID: 32825881
[TBL] [Abstract][Full Text] [Related]
14. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.
Ho HT; Wang TH; Hsiong CH; Perng WC; Wang NC; Huang TY; Jong YJ; Lu PL; Hu OY
Pharmacogenet Genomics; 2013 Apr; 23(4):200-7. PubMed ID: 23407048
[TBL] [Abstract][Full Text] [Related]
15. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
[TBL] [Abstract][Full Text] [Related]
16. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
[No Abstract] [Full Text] [Related]
17. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.
Kim SH; Kim SH; Bahn JW; Kim YK; Chang YS; Shin ES; Kim YS; Park JS; Kim BH; Jang IJ; Song J; Kim SH; Park HS; Min KU; Jee YK
Pharmacogenomics; 2009 Nov; 10(11):1767-79. PubMed ID: 19891553
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic association between
Khan S; Mandal RK; Elasbali AM; Dar SA; Jawed A; Wahid M; Mahto H; Lohani M; Mishra BN; Akhter N; Rabaan AA; Haque S
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509962
[TBL] [Abstract][Full Text] [Related]
19. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
